Reappraisal of Antihypertensive Medicine Doxazosin and Carvedilol as a Potential Therapeutic for Hepatic Fibrosis

참고문헌 (11)

1. Paik YH, "Role of NADPH oxidases in liver fibrosis", Antioxid Redox Signal, 20, pp.2854~2872 (2014)
2. Mehal WZ, "Antifibrotic therapies in the liver", Semin Liver Dis, 35, pp.184~198 (2015)
3. Kim MY, "Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis: a randomized open-label controlled study", Liver Int, 32, pp.977~987 (2012)
4. Martin Humberto Muñoz-Ortega, "Doxazosin Treatment Attenuates Carbon Tetrachloride-Induced Liver Fibrosis in Hamsters through a Decrease in Transforming Growth Factor β Secretion", Gut and Liver, 10(1), pp.101~108 (2016), 거트앤리버 발행위원회
5. Oben JA, "Hepatic fibrogenesis requires sympathetic neurotransmitters", Gut, 53, pp.438~445 (2004)
6. Sancho-Bru P, "Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells", Am J Physiol Gastrointest Liver Physiol, 291, pp.G877~G884 (2006)
7. Sigala B, "Sympathetic nervous system catecholamines and neuropeptide Y neurotransmitters are upregulated in human NAFLD and modulate the fibrogenic function of hepatic stellate cells", PLoS One, 8, pp.e72928~ (2013)
8. Sokol SI, "Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure", J Clin Pharmacol, 40, pp.11~30 (2000)
9. Bañares R, "Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis", Hepatology, 36, pp.1367~1373 (2002)
10. Mandorfer M, "Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis", Gastroenterology, 146(e1), pp.1680~1690 (2014)
11. Leithead JA, "Non-selective beta-blockers are associated with improved survival in patients with ascites listed for liver transplantation", Gut, 64, pp.1111~1119 (2015)